Skip to main content
. 2017 Oct 6;8(55):94069–94079. doi: 10.18632/oncotarget.21578

Figure 3. Silencing of miR-21 ameliorates the clinical severity of EAE.

Figure 3

(A) Mean clinical score and weight loss of B6 EAE mice treated with antagomiR-21 or the negative control. The data represent one experiment and are presented as the mean ± SEM. (B) The miR-21 expression level was analyzed by qRT-PCR using the U6 snRNA as an endogenous control. (C) Spinal cord histology was analyzed on day 14 after immunization. The degree of inflammation in the negative-control-treated mice (left) and antagomiR-21-treated mice (right) was determined by H&E staining. The pictures shown are representative of the spinal cord histology of 3 mice in each group. (D) Splenocytes obtained from antagomiR-21-treated and negative-control-treated EAE mice were restimulated with PMA/ionomycin/monensin/LPS for 5 h. The data are representative of 3 independent experiments. *P < 0.05.

HHS Vulnerability Disclosure